Anant Madabhushi

Madabhushi received a bachelor's degree in biomedical engineering from Mumbai University, India in 1998 and a master's degree in biomedical engineering from the University of Texas, Austin in 2000. In 2004, he received his PhD in bioengineering from the University of Pennsylvania.[9]

Madabhushi joined the Department of Biomedical Engineering at Rutgers University as an assistant professor in 2005. He became an associate professor with tenure in 2010. In 2012, he left Rutgers and joined Case Western Reserve University’s Department of Biomedical Engineering as an associate professor. He became a full professor in 2014 and moved to the position of F. Alex Nason professor II endowed chair of biomedical engineering in 2016. In 2020, he moved to the position of Donnell Institute Professor. Madabhushi also serves as the director of the university’s Center for Computational Imaging and Personalized Diagnostics (CCIPD).[10]

Madabhushi has secured $50 million in grant funding and co-founded two companies, Vascuvis Inc. (now Elucid Bioimaging) and IbRiS Inc., a start up company focused on developing image-based assays for breast cancer prognosis. IbRiS was acquired by Inspirata[11] in 2015. Madabhushi has been involved in sponsored research and industry partnerships with Siemens, Philips and GE, as well as collaborations with pharmaceutical companies including Astrazeneca, Boehringer Ingelheim and Bristol-Myers Squibb. Fifteen technologies developed by Madabhushi’s team have been licensed.[1]

Madabhushi has written more than 200 peer-reviewed journal publications, appearing in journals such as Nature Reviews Clinical Oncology, Nature Reviews Drug Discovery, Radiology, Scientific Reports, American Journal of Surgical Pathology, the Annual Review of Biomedical Engineering, Medical Image Analysis, IEEE Transactions on Medical Imaging and PLOS One. He has authored over 200 papers for conferences including SPIE Medical Imaging, the Medical Image Computing and Computer Assisted Intervention (MICCAI) Conference and the International Symposium on Biomedical Imaging (ISBI).[12] Madabhushi was the conference chair for the Digital Pathology Conference held in conjunction with the SPIE Medical Imaging Symposium between 2013-2016.[13]

Madabhushi has delivered 325 invited talks and lectures in the United States and abroad. In June 2019 he delivered the Annual Pritzker Lecture at Mount Sinai Hospital in Toronto. He delivered the keynote lecture at the ASCO Breakthrough Summit[14] in Bangkok in October 2019. He has served as an associate Editor for IEEE Transactions on Biomedical Engineering, IEEE Transactions on Biomedical Engineering Letters, BMC Cancer, BMC Medical Imaging, the Journal of Medical Imaging and Medical Image Analysis (MedIA).

Madabhushi has 100 patents either issued or pending in the areas of medical image analysis, computer-aided diagnosis and computer vision. In March 2017, he was issued a patent for “Textural analysis of lung nodules”[15] covering methods and apparatus for classifying a region of tissue using textural analysis so a patient prognosis can be made based on the classification of the image. In January 2017, he was issued a patent for “Histogram of hosoya index (HoH) features for quantitative histomorphometry),”[16] an invention that captures cancer architecture in digital pathology images and can help differentiate between more and less aggressive early stage, estrogen receptor positive breast cancers. In 2019 Patent US 10,398,399 entitled "Decision support for disease characterization and treatment response with disease and peri-disease radiomics" was issued to the Center for Computational Imaging and Personalized Diagnostics.[17]

Madabhushi has received the Department of Defense New Investigator Award in Lung Cancer (2014); The Excellence in Teaching Award (2007-2009) from Rutgers University; and the Coulter Phase 1 and Phase 2 Early Career award (2006, 2008).[18] He also was the recipient of an Early Career Award from the Society of Imaging Informatics in Medicine (SIIM) in 2009.[19]

In 2015, Madabhushi was named one of the “Forty under 40” people making a positive impact on business in northeast Ohio by Crain’s Cleveland Business magazine. He is a Wallace H. Coulter Fellow, a Fellow of the National Academy of Inventors, a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and an IEEE Fellow. In 2019 and 2020, Madabhushi was named to The Pathologist's Power List, a list of 100 inspiring professionals in pathology and laboratory medicine.[20]

With Madabhushi as founding director, the team at Case Western Reserve University’s Center for Computational Imaging and Personalized Diagnostics (CCIPD) is developing image analysis, statistical pattern recognition, machine learning and artificial intelligence tools to computationally interrogate biomedical image data, including MRI, CAT scans and digital pathology tissue images. The tools can be used to predict disease progression and provide a score to clinicians on the aggressiveness of a patient’s disease, such as breast cancer and prostate cancer, which can in turn help physicians decide on appropriate treatment options.[21]

The impetus for the CCIPD’s systems-based approach to disease understanding is to diverge from a traditional approach of focusing on a limited number of molecular components to a broader understanding of how numerous interrelated health variables – proteomics, metabolites, genomics – result in the emergence of definable phenotypes. Work done under Madabhushi’s guidance has yielded results, including the discovery of computationally-derived image biomarkers that pave the way for disease prognosis and therapeutic response, thereby allowing physicians to predict which treatment and management strategies might be most appropriate.[22] In addition, research on image biomarkers is being applied by the CCIPD group to the field of “radiogenomics”[23] or predicting the mutational status or molecular subtype[24] of a tumor based solely off computational features derived from a routine imaging scan. Dr. Madabhushi’s team has pioneered the Ibris (image based risk score),[25] which computes the probability of disease aggressiveness using features mined from medical images for a variety of cancers.[26][27][28][29]

Madabhushi’s research has received grant funding from the National Cancer Institute (NIH), National Science Foundation, the Department of Defense, private foundations and industry.